Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 7 studies | 18% ± 2% | |
endothelial cell | 7 studies | 20% ± 4% | |
naive B cell | 5 studies | 16% ± 1% | |
epithelial cell | 5 studies | 29% ± 10% | |
regulatory T cell | 5 studies | 18% ± 2% | |
CD8-positive, alpha-beta T cell | 5 studies | 19% ± 2% | |
CD4-positive, alpha-beta T cell | 4 studies | 21% ± 1% | |
fibroblast | 4 studies | 18% ± 2% | |
glutamatergic neuron | 4 studies | 38% ± 14% | |
astrocyte | 4 studies | 21% ± 5% | |
CD4-positive, alpha-beta memory T cell | 3 studies | 16% ± 1% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 19% ± 3% | |
mucosal invariant T cell | 3 studies | 18% ± 1% | |
ciliated cell | 3 studies | 24% ± 4% | |
GABAergic neuron | 3 studies | 38% ± 5% | |
oligodendrocyte precursor cell | 3 studies | 24% ± 6% | |
dendritic cell | 3 studies | 23% ± 5% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 18% ± 2% | |
gamma-delta T cell | 3 studies | 29% ± 17% | |
basal cell | 3 studies | 25% ± 2% | |
interneuron | 3 studies | 36% ± 14% | |
neuron | 3 studies | 21% ± 3% | |
oligodendrocyte | 3 studies | 17% ± 1% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 16% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1061.35 | 1445 / 1445 | 100% | 29.90 | 183 / 183 |
ovary | 100% | 1301.06 | 180 / 180 | 100% | 21.31 | 430 / 430 |
stomach | 100% | 840.24 | 359 / 359 | 100% | 26.60 | 286 / 286 |
intestine | 100% | 1111.34 | 966 / 966 | 100% | 27.33 | 526 / 527 |
breast | 100% | 1271.75 | 459 / 459 | 100% | 27.18 | 1115 / 1118 |
lung | 100% | 1077.22 | 576 / 578 | 100% | 25.90 | 1155 / 1155 |
uterus | 100% | 1288.76 | 170 / 170 | 100% | 24.39 | 457 / 459 |
thymus | 100% | 1104.18 | 653 / 653 | 99% | 16.42 | 598 / 605 |
bladder | 100% | 1295.95 | 21 / 21 | 99% | 23.27 | 498 / 504 |
prostate | 100% | 1066.09 | 245 / 245 | 99% | 16.13 | 495 / 502 |
brain | 99% | 602.68 | 2606 / 2642 | 100% | 16.16 | 703 / 705 |
skin | 100% | 1558.81 | 1809 / 1809 | 98% | 28.54 | 463 / 472 |
pancreas | 99% | 541.76 | 325 / 328 | 99% | 15.80 | 176 / 178 |
kidney | 100% | 828.83 | 89 / 89 | 95% | 12.89 | 853 / 901 |
adrenal gland | 100% | 895.98 | 258 / 258 | 94% | 12.50 | 216 / 230 |
liver | 100% | 486.48 | 226 / 226 | 85% | 8.60 | 347 / 406 |
adipose | 100% | 1256.54 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 25.08 | 29 / 29 |
muscle | 100% | 937.65 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1308.56 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 27.98 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.21 | 1 / 1 |
blood vessel | 100% | 880.08 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 542.84 | 843 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 89% | 19.43 | 71 / 80 |
peripheral blood | 83% | 949.22 | 773 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0022613 | Biological process | ribonucleoprotein complex biogenesis |
GO_0000387 | Biological process | spliceosomal snRNP assembly |
GO_0036261 | Biological process | 7-methylguanosine cap hypermethylation |
GO_0015030 | Cellular component | Cajal body |
GO_0005730 | Cellular component | nucleolus |
GO_0005615 | Cellular component | extracellular space |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0030532 | Cellular component | small nuclear ribonucleoprotein complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008173 | Molecular function | RNA methyltransferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0071164 | Molecular function | RNA cap trimethylguanosine synthase activity |
Gene name | TGS1 |
Protein name | Trimethylguanosine synthase 1 Trimethylguanosine synthase (EC 2.1.1.-) (CLL-associated antigen KW-2) (Cap-specific guanine-N2 methyltransferase) (Hepatocellular carcinoma-associated antigen 137) (Nuclear receptor coactivator 6-interacting protein) (PRIP-interacting protein with methyltransferase motif) (PIMT) (PIPMT) |
Synonyms | PIMT NCOA6IP HCA137 |
Description | FUNCTION: Catalyzes the 2 serial methylation steps for the conversion of the 7-monomethylguanosine (m(7)G) caps of snRNAs and snoRNAs to a 2,2,7-trimethylguanosine (m(2,2,7)G) cap structure. The enzyme is specific for guanine, and N7 methylation must precede N2 methylation. Hypermethylation of the m7G cap of U snRNAs leads to their concentration in nuclear foci, their colocalization with coilin and the formation of canonical Cajal bodies (CBs). Plays a role in transcriptional regulation. . |
Accessions | ENST00000260129.6 Q96RS0 E5RJW7 ENST00000523948.5 |